GlassScriptPhysician profile
Charles Roberts
NPI 1366456162
$4,587.88
in general payments reported to CMS, 2019-2025
28 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,228 · 2020: $685 · 2021: $455 · 2022: $132 · 2023: $1,004 · 2024: $923 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,314 · Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,314.18 |
| Food and Beverage | $773.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,335.01 | 2019-2024 | Superion Indirect Decompression System |
| Relievant Medsystems, INC. | $885.12 | 2023 | Intracept |
| Abbott Laboratories | $496.12 | 2019-2020 | |
| Nevro Corp. | $265.59 | 2019-2020 | |
| Medtronic USA, INC. | $195.41 | 2019-2020 | |
| Medtronic, INC. | $187.04 | 2021-2025 | Synchromedii, Bis |
| Scilex Pharmaceuticals INC. | $177.79 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $145.06 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $117.97 | 2019-2024 | Xtampza |
| Teva Pharmaceuticals USA, INC. | $109.75 | 2019-2020 | |
| Amgen INC. | $103.66 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.83 | 2019-2024 | Relistor |
| Abbvie INC. | $56.82 | 2021-2024 | |
| Si-Bone, INC. | $55.71 | 2019-2025 | |
| Vertex Pharmaceuticals Incorporated | $55.60 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $49.24 | 2019 | |
| Grt US Holding, INC. | $48.46 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $48.26 | 2021 | |
| Mdd US Operations, LLC | $35.25 | 2019-2020 | |
| Pfizer INC. | $25.33 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $24.35 | 2021 | |
| Chiesi USA, INC. | $23.50 | 2023 | Cleviprex |
| Merck Sharp & Dohme LLC | $18.92 | 2025 | Bridion |
| Biodelivery Sciences International, INC. | $15.41 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.52 | 2019 | |
| Flowonix Medical Incorporated | $12.93 | 2020 | |
| Horizon Therapeutics Plc | $10.86 | 2019 | |
| Spr Therapeutics, INC | $10.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.